831 Proteasome inhibitor functional profiling in CTCL

Abstract

Cutaneous T-cell lymphoma (CTCL) is a non-Hodgkin T-cell lymphoma that presents with skin manifestations and is often incurable at advanced stages with blood involvement. Genomic profiling of malignant cells from CTCL patients has revealed a diverse range of genetic mutations underlying the disease, including single nucleotide mutations and gene copy number alterations involving the JAK/STAT and NF-κB signaling pathways. Synergistic drug combination treatment in CTCL may allow for the targeting of multiple aberrant pathways while minimizing toxicity and single-agent resistance.